A Phase III, Prospective, Randomized, Modified Double-Blind, Comparative Trial Assessing the Immunogenicity and Reactogenicity of a Tetanus-Diphtheria 5-Component (Pertussis Toxoid, Filamentous Hemagglutinin, Pertactin, and Fimbriae Types 2 and 3) Acellular Pertussis Vaccine (Tdap) in Healthy Adolescents and Adults.
Phase of Trial: Phase III
Latest Information Update: 05 Apr 2018
At a glance
- Drugs DTaP vaccine (Primary) ; Diphtheria-tetanus vaccine
- Indications Diphtheria; Pertussis; Tetanus
- Focus Pharmacodynamics; Registrational
- Sponsors sanofi pasteur
- 05 Apr 2018 New trial record
- 02 Jun 2005 Results published in the JAMA: the Journal of the American Medical Association.